奥翔药业(603229) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥197,732,625.25, a decrease of 2.57% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was ¥49,153,279.42, down 24.54% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥40,347,450.36, a decline of 31.86% compared to the previous year[2] - The basic earnings per share for Q3 2024 was ¥0.06, a decrease of 25.00% compared to the same period last year[2] - The diluted earnings per share for Q3 2024 was also ¥0.06, reflecting a 25.00% decline year-on-year[2] - The weighted average return on equity for Q3 2024 was 2.08%, down 0.94 percentage points from the previous year[2] - Total operating revenue for the first three quarters of 2024 reached ¥690,126,439.62, an increase of 2.1% compared to ¥671,662,047.60 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was ¥228,985,673.66, slightly higher than ¥225,337,632.82 in the previous year, marking an increase of 1.2%[16] - Basic and diluted earnings per share for the first three quarters were both ¥0.28, up from ¥0.27 in the previous year[16] Cash Flow and Investments - The net cash flow from operating activities for Q3 2024 was ¥44,971,218.04, with a significant increase of 715.67% year-to-date[2][6] - Cash flow from operating activities generated a net amount of ¥83,903,512.00, significantly up from ¥10,286,467.01 in the same period last year[18] - The net cash flow from investing activities was -85,649,460.36 CNY, compared to -110,201,806.79 CNY in the previous period[19] - The net cash flow from financing activities was -87,164,842.07 CNY, a significant decrease from 476,081,825.00 CNY in the prior period[19] - The cash inflow from financing activities totaled 170,100,000.00 CNY, down from 685,101,683.16 CNY in the previous period[19] - The cash outflow for debt repayment was 170,000,000.00 CNY, compared to 131,230,000.00 CNY in the prior period[19] - The cash outflow for dividend distribution and interest payments was 82,175,406.89 CNY, an increase from 55,306,345.33 CNY in the previous period[19] - The total cash outflow from investing activities was 97,166,549.70 CNY, compared to 116,316,552.85 CNY in the previous period[19] - The initial cash and cash equivalents balance was 1,088,001,587.93 CNY, leading to a net decrease of 94,431,413.49 CNY during the period[19] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥3,017,623,921.65, reflecting a 2.24% increase from the end of the previous year[3] - The equity attributable to shareholders at the end of Q3 2024 was ¥2,294,063,644.31, up 7.12% year-on-year[3] - The company's cash and cash equivalents amounted to CNY 1.03 billion, down from CNY 1.12 billion, indicating a decrease of approximately 8.8%[12] - Accounts receivable increased to CNY 293.74 million from CNY 132.75 million, representing a significant rise of about 109.5%[12] - The total liabilities decreased to CNY 723.56 million from CNY 809.99 million, showing a reduction of approximately 10.7%[14] - The equity attributable to shareholders rose to CNY 2.29 billion from CNY 2.14 billion, marking an increase of about 7%[14] - Inventory levels slightly decreased to CNY 363.36 million from CNY 365.18 million, a decline of about 0.5%[13] - The company reported a decrease in accounts payable from CNY 301.09 million to CNY 225.72 million, a decline of approximately 25%[13] - The company’s retained earnings increased to CNY 919.64 million from CNY 767.16 million, indicating a growth of about 20%[14] Operating Costs and Expenses - Total operating costs increased to ¥436,562,072.07, up from ¥419,225,427.62, reflecting a rise of 4.1%[15] - Research and development expenses decreased to ¥64,018,512.40 from ¥73,686,399.20, a reduction of 13.2%[15] - Tax expenses increased to ¥32,293,813.73 from ¥30,947,389.88, reflecting a rise of 4.4%[16] Other Financial Metrics - Non-recurring gains and losses for Q3 2024 totaled ¥8,805,829.06, compared to ¥16,336,376.43 year-to-date[5] - The company reported a financial income of ¥11,517,089.34, compared to ¥5,799,465.05 in the previous year, showing an increase of 98.5%[18] - Total comprehensive income for the first three quarters of 2024 was ¥228,993,041.39, compared to ¥225,421,153.05 in the same period of 2023[16]